The US Food and Drug Administration has recently approved the direct-to-consumer sale of a new 23andMe DNA test geared toward assessing people's risk of breast cancer, marking the first time that consumers have been able to get such a test without having to consult a physician first.
The test analyzes genes known as BRCA1 and BRCA2, variants of which have been tied to the risk of developing breast cancer. The FDA notes that the 23andMe DNA test only reports on the three variants most common to people of Ashkenazi Jewish descent (i.e. Jews from Eastern Europe), and that there are more than 1,000 known BRCA mutations among the general population. In other words, "a negative result does not rule out the possibility that an individual carries other BRCA mutations that increase cancer risk".
Nonetheless, this direct-to-consumer test can help people in potentially high-risk demographics (like Ashkenazi Jewish women) to screen themselves early.
DNA-Based Cancer Risk Tests
More Stats +/-
Future Festival & Malcolm Gladwell - Early Bird Deadline
DNA-Based Eating Plans
DIY Biodesign Kits
Genetic Vitamin Companies
Hyper-Targeted Antimicrobial Pills
Free 2018 Report & eBook
Get the top 100 trends happening right NOW -- plus a FREE copy of our award-winning book.
Our Research Methodology
This article is one of 350,000 experiments. We use crowd filtering, big data and AI to identify insights.